Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States.
+ 1 more risk
Flawless balance sheet with limited growth.
Share Price & News
How has Synlogic's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SYBX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: SYBX underperformed the US Biotechs industry which returned 1.8% over the past year.
Return vs Market: SYBX underperformed the US Market which returned -10.4% over the past year.
Price Volatility Vs. Market
How volatile is Synlogic's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StSynlogic, Inc. (NASDAQ:SYBX) Analysts Just Slashed Next Year's Revenue Estimates By 39%
2 weeks ago | Simply Wall StSynlogic, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report
1 month ago | Simply Wall StThe Synlogic (NASDAQ:SYBX) Share Price Is Down 73% So Some Shareholders Are Rather Upset
Is Synlogic undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SYBX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SYBX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SYBX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SYBX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SYBX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SYBX is good value based on its PB Ratio (0.4x) compared to the US Biotechs industry average (2.6x).
How is Synlogic forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYBX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SYBX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SYBX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SYBX's revenue (64.1% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: SYBX's revenue (64.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SYBX's Return on Equity is forecast to be high in 3 years time
How has Synlogic performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYBX is currently unprofitable.
Growing Profit Margin: SYBX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SYBX is unprofitable, and losses have increased over the past 5 years at a rate of -28.2% per year.
Accelerating Growth: Unable to compare SYBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SYBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: SYBX has a negative Return on Equity (-32.74%), as it is currently unprofitable.
How is Synlogic's financial position?
Financial Position Analysis
Short Term Liabilities: SYBX's short term assets ($133.2M) exceed its short term liabilities ($8.9M).
Long Term Liabilities: SYBX's short term assets ($133.2M) exceed its long term liabilities ($22.8M).
Debt to Equity History and Analysis
Debt Level: SYBX is debt free.
Reducing Debt: SYBX has not had any debt for past 5 years.
Inventory Level: SYBX has a low level of unsold assets or inventory.
Debt Coverage by Assets: SYBX's debt is not covered by short term assets (assets are -3.7505414746788E+16x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SYBX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SYBX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -42% each year.
What is Synlogic's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SYBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SYBX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SYBX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SYBX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SYBX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Aoife Brennan (43yo)
Dr. Aoife M. Brennan, M.D. M.B., B.Ch. has been a Director at Ra Pharmaceuticals, Inc since September 21, 2018. Dr. Brennan has been the President, Chief Executive Officer & Director of Synlogic Inc. sinc ...
CEO Compensation Analysis
Compensation vs Market: Aoife's total compensation ($USD2.12M) is above average for companies of similar size in the US market ($USD602.37K).
Compensation vs Earnings: Aoife's compensation has increased whilst the company is unprofitable.
|Executive Chairman||3yrs||US$134.75k||no data|
|no data||US$1.39m||1.09% $648.8k|
|Co-Founder||no data||no data||no data|
|Co-Founder||no data||no data||no data|
|Interim CFO||0.42yr||no data||no data|
|Head of Technical Operations||1.25yrs||no data||no data|
|Head of Investor Relations & Corporate Communications||no data||no data||no data|
|Vice President of Corporate Development||3.58yrs||no data||no data|
|Chief Human Resources Officer||2.42yrs||no data||no data|
Experienced Management: SYBX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Executive Chairman||3yrs||US$134.75k||no data|
|Independent Director||7.42yrs||US$108.49k||no data|
|Independent Director||2.58yrs||US$108.49k||0.023% $13.8k|
|Independent Director||7.42yrs||US$103.49k||no data|
|Independent Director||4yrs||US$102.24k||no data|
|Independent Director||4yrs||US$98.49k||0.072% $42.6k|
|Member Scientific Advisory Board||no data||US$436.81k||0.15% $88.6k|
|Observer||no data||no data||no data|
|Independent Director||1yr||no data||no data|
Experienced Board: SYBX's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.8%.
Synlogic, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Synlogic, Inc.
- Ticker: SYBX
- Exchange: NasdaqGM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$59.341m
- Shares outstanding: 32.25m
- Website: https://www.synlogictx.com
Number of Employees
- Synlogic, Inc.
- 301 Binney Street
- Suite 402
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MINA||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Aug 2017|
|SYBX||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Aug 2017|
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. The company also has a clinical collaboration with Hoffman-La Roche Ltd. to evaluate SYNB1891 in combination with PD-L1 checkpoint inhibitor in patients with advanced solid tumors. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 02:19|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.